Literature DB >> 21937679

Human breast tumor cells induce self-tolerance mechanisms to avoid NKG2D-mediated and DNAM-mediated NK cell recognition.

Emilie Mamessier1, Aude Sylvain, François Bertucci, Rémy Castellano, Pascal Finetti, Gilles Houvenaeghel, Emmanuelle Charaffe-Jaufret, Daniel Birnbaum, Alessandro Moretta, Daniel Olive.   

Abstract

Breast cancer is the leading cause of death for women between the ages of 35 to 65. This is mostly due to intertumor heterogeneity and the lack of specific therapies for all subtypes. However, some breast cancers with an unexpected good prognosis are associated with enhanced antitumor immunity in situ. We studied whether breast cancer subtypes might have different susceptibilities to natural killer (NK) cells' antitumor immunity. We collected a large public set of microarray data for primary breast tumors and determined NK cell ligand expression. We found that despite heterogeneous levels of inhibitory HLA members, NKG2D ligands and DNAM ligands are expressed in virtually all breast tumor subtypes. Functional experiments in breast cancer subtypes expressing various levels of NK cell ligands showed that NK-mediated cytotoxicity is mainly HLA, NKG2D, and DNAM dependent. In parallel, we showed that cell lines and primary breast tumor cells secrete soluble inhibitory factors that alter NK cell functions. Finally, we showed that these mechanisms of escape occur in vivo in the MMTV-Neu model of spontaneous murine breast cancer. Our study shows that breast cancer cells, independent of the subtype, have developed different mechanisms to escape from NK cells' antitumor immunity. These results emphasize the role of NK cells in breast tumor clearance and underlie the importance of devising future therapy aiming at enhancing NK cell-mediated recognition in parallel with the prevention of the tumor-editing process. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21937679     DOI: 10.1158/0008-5472.CAN-11-0792

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  47 in total

1.  IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma.

Authors:  Joe-Marc Chauvin; Mignane Ka; Ornella Pagliano; Carmine Menna; Quanquan Ding; Richelle DeBlasio; Cindy Sanders; Jiajie Hou; Xian-Yang Li; Soldano Ferrone; Diwakar Davar; John M Kirkwood; Robert J Johnston; Alan J Korman; Mark J Smyth; Hassane M Zarour
Journal:  Clin Cancer Res       Date:  2020-06-26       Impact factor: 12.531

2.  Primary B-CLL resistance to NK cell cytotoxicity can be overcome in vitro and in vivo by priming NK cells and monoclonal antibody therapy.

Authors:  Caroline Veuillen; Thérèse Aurran-Schleinitz; Rémy Castellano; Jérôme Rey; Françoise Mallet; Florence Orlanducci; Laurent Pouyet; Sylvaine Just-Landi; Diane Coso; Vadim Ivanov; Xavier Carcopino; Réda Bouabdallah; Yves Collette; Cyril Fauriat; Daniel Olive
Journal:  J Clin Immunol       Date:  2012-02-09       Impact factor: 8.317

Review 3.  The Multifaceted Nature of Tumor Microenvironment in Breast Carcinomas.

Authors:  Laura Annaratone; Eliano Cascardi; Elena Vissio; Ivana Sarotto; Ewa Chmielik; Anna Sapino; Enrico Berrino; Caterina Marchiò
Journal:  Pathobiology       Date:  2020-04-23       Impact factor: 4.342

Review 4.  Molecular mechanisms of natural killer cell activation in response to cellular stress.

Authors:  C J Chan; M J Smyth; L Martinet
Journal:  Cell Death Differ       Date:  2013-04-12       Impact factor: 15.828

5.  Circulating NKp46+ Natural Killer cells have a potential regulatory property and predict distinct survival in Non-Small Cell Lung Cancer.

Authors:  Emilie Picard; Yann Godet; Caroline Laheurte; Magalie Dosset; Jeanne Galaine; Laurent Beziaud; Romain Loyon; Laura Boullerot; Elodie Lauret Marie Joseph; Laurie Spehner; Marion Jacquin; Guillaume Eberst; Béatrice Gaugler; Françoise Le Pimpec-Barthes; Elizabeth Fabre; Virginie Westeel; Anne Caignard; Christophe Borg; Olivier Adotévi
Journal:  Oncoimmunology       Date:  2018-10-19       Impact factor: 8.110

6.  Blockade of CD112R and TIGIT signaling sensitizes human natural killer cell functions.

Authors:  Feng Xu; Alexander Sunderland; Yue Zhou; Richard D Schulick; Barish H Edil; Yuwen Zhu
Journal:  Cancer Immunol Immunother       Date:  2017-06-16       Impact factor: 6.968

Review 7.  Targeting novel inhibitory receptors in cancer immunotherapy.

Authors:  Quan-Quan Ding; Joe-Marc Chauvin; Hassane M Zarour
Journal:  Semin Immunol       Date:  2020-12-04       Impact factor: 11.130

Review 8.  NKG2D ligands as therapeutic targets.

Authors:  Paul Spear; Ming-Ru Wu; Marie-Louise Sentman; Charles L Sentman
Journal:  Cancer Immun       Date:  2013-05-01

Review 9.  Natural killer cell receptors: alterations and therapeutic targeting in malignancies.

Authors:  Gordana Konjević; Ana Vuletić; Katarina Mirjačić Martinović
Journal:  Immunol Res       Date:  2016-02       Impact factor: 2.829

10.  Machine learning-aided quantification of antibody-based cancer immunotherapy by natural killer cells in microfluidic droplets.

Authors:  Saheli Sarkar; Wenjing Kang; Songyao Jiang; Kunpeng Li; Somak Ray; Ed Luther; Alexander R Ivanov; Yun Fu; Tania Konry
Journal:  Lab Chip       Date:  2020-06-30       Impact factor: 6.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.